Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three noninterventional studies;Wirksamkeit und Verträglichkeit einer intravenösen Eisentherapie bei geriatrischen Patienten mit Anämie: Gepoolte Daten aus drei nicht-interventionellen Studien

MMW-Fortschritte der Medizin

Volumn 156, Issue , 2014, Pages 48-53

  Röhrig Herzog, Gabriele ^a   Steinmetz, Tilmann ^b   Stein, Jürgen ^c   Geisel, Tabea ^d   Virgin, Garth ^e   Schaefer, Roland ^f   Bach, Matthias ^d   Schulz, Ralf Joachim ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Praxis für OnkoLogie und Hämatologie Onkologie Koln   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d St Elisabethen Krankenhaus   (Germany)

^e Vifor (International) Inc   (Switzerland)

^f Eisenzentrum   (Germany)

Author keywords

Anemia; Functional iron deficiency; Geriatrics; Intravenous; Iron

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; TRANSFERRIN; FERRIC ION; MALTOSE;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FERRITIN BLOOD LEVEL; GERIATRIC PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENTAL CAPACITY; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; FEMALE; FOLLOW UP; GERMANY; HEMOGLOBIN DETERMINATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; GERMANY; HEMOGLOBINOMETRY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MALTOSE; TRANSFERRIN;

EID: 84921975708     PISSN: 14383276     EISSN: 16133560     Source Type: Journal    
DOI: 10.1007/s15006-014-3226-0     Document Type: Article

References (33)

1. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis 7 (2005), 398-402.
2. Beghé C, Wilson A, Ershler WB. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med 116 Suppl 7A (2004), 3S-10S.
3. Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 100 (2008), 599-604.
4. Blanc B, Finch CA, Hallberg L. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 405 (1968), 1-40.
5. Den Elzen WP, de Craen AJ, Wiegerinck ET, Westendorp RG, Swinkels DW, Gussekloo J. Plasma hepcidin levels and anemia in old age. The Leiden 85-plus Study. Haematologica 98 (2013), 448-454.
6. Evstatiev R, Marteau P, Iqbal T, et al.; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 141 (2011), 846-853.
7. Ferreiro-Iglesias R, Barreiro-de-Acosta M, Seijo-Ríos S, Lorenzo A, Domínguez-Muñoz JE. Efficacy of intravenous iron in treating iron deficiency anaemia in patients with inflammatory bowel disease. Are there predictors of response? Rev Esp Enferm Dig 103 (2011), 245-249.
8. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia-systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52 (2013), 18-29.
9. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 1823(9) (2012), 1434-1443.
10. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104 (2004), 2263-2268.
11. Hastka J, Heimpel H, Metzgeroth G. DGHO-Leitlinien zu Eisenmangel und Eisenmangelanämie. http:// www.dgho-onkopedia.de/de/onkopedia/leitlinien/ eisenmangel-und-eisenmangelanaemie/index_html (aufgesucht am 13.06.2014).
12. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 103 (2008), 1182-1192.
13. Lucca U, Tettamanti M, Mosconi P, et al. Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS One 3 (2008), e1920.
14. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40 (2004), 2293-2306.
15. Macdougall IC. Iron supplementation in nephrology and oncology: what do we have in common? Oncologist 16 Suppl 3 (2011), 25-34.
16. Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, HasuikeY. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 16 (2012), 819-826.
17. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 15 (2008), 169-175.
18. Pang WW, Schrier SL. Anemia in the elderly. Curr Opin Hematol 19 (2012), 133-140.
19. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of nondialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 26 (2011), 1599-1607.
20. Röhrig G, Nobbe C, Weiß V, Schulz RJ. Hepcidin in anaemic geriatric patients with non-dialysis chronic kidney disease (ND-CKD). Eur Geriatric Med 4 (2013), 221-225.
21. Röhrig G, Schulz RJ. Anämie im Alter-es besteht dringlicher Bedarf an einer Leitlinie. Z Gerontol Geriat 45 (2012), 182-185.
22. Schröder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 100 (2005), 2503-2509.
23. Smith DL. Anemia in the elderly. Am Fam Physician 62 (2000), 1565-1572.
24. Stein J, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Hartmann F. Behandlung der Eisenmangelanämie bei chronischen Erkrankungen mit Eisencarboxymaltose: Ergebnisse aus drei nicht-interventionellen Studien in der Onkologie, Gastroenterologie und Nephrologie. Kongress der Deutschen Gesellschaft für Innere Medizin Mannheim 2011; Poster PS112.
25. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer-and chemotherapy-associated anaemia. Ann Oncol 29 (2013), 475-482
26. Stolz HP, Raffelsiefer A, Schaefer RM. Therapie des Eisenmangels mit Eisencarboxymaltose bei Patienten mit nicht-dialysepflichtiger chronischer Nierenerkrankung. Nieren-und Hochdruckkrankheiten 42 (2013), 173-181.
27. Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 39 (2009), 883-890.
28. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 12 (2006), 123-130.
29. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4 (2009), 1051-1556.
30. Richtlinie 2001 /83 /EG, Artikel 1 und § 4 Abs. 13 Arzneimittelgesetz (AMG).
31. The National Comprehensive Cancer Network (NCCN), www.nccn.org (aufgesucht am 16.05.2014).
32. Kidney Disease / Improving Global Outcomes, www.kdigo.org (aufgesucht am 16.05.2014).
33. European Crohn’s and Colitis Organisation / Inflammatory Bowel Diseases, www.ecco-ibd.eu (aufgesucht am 16.05.2014).